{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040136","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.121115+00:00","generated_at":"2026-06-11T21:54:06.318046+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aura Biosciences Q2 net loss $18.3M; cash $162M; Phase 3 trial on track for H2 2023 dosing","bullets":["Net loss $18.3M vs $13.5M in Q2 2022; R&D expenses rose to $15.1M on Phase 3 start-up.","Cash and marketable securities $162.0M; expected to fund operations into H2 2025.","Phase 3 trial of bel-sar for choroidal melanoma enrolling; first patient dosing expected H2 2023; commercial material released.","Key leadership appointments: Bruce Brown (Urologic Oncology), Anthony Daniels (Ocular Oncology), Richard Mountfield (SVP Regulatory).","Phase 1 NMIBC trial ongoing; data expected 2024; Plan Phase 2 in choroidal metastasis in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040136","json":"https://secwatch.observer/filing/0000950170-23-040136.json","markdown":"https://secwatch.observer/filing/0000950170-23-040136.md","text":"https://secwatch.observer/filing/0000950170-23-040136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/0000950170-23-040136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/aura-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:54:06.318046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33751378cd906ee3e512096dead87e815808ccfe","claim":"Aura Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $18.3 million.","evidence_excerpt":"On August 9, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/0000950170-23-040136-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023 was $18.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}